Please use this identifier to cite or link to this item: https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/702
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrowning, Michael-
dc.date.accessioned2021-01-05T18:37:30Z-
dc.date.available2021-01-05T18:37:30Z-
dc.date.issued2017-02-
dc.identifier.citationBrowning, M., 2017. Symptom trajectories in discontinuation trials. Lancet Psychiatry 4, 176–178en
dc.identifier.issn2215-0366-
dc.identifier.urihttps://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/702-
dc.description.abstractMany patients with clinical depression, particularly those with recurrent illness, are treated with maintenance antidepressants after an acute-phase response. But how effective is this approach? The effectiveness of maintenance treatment is most commonly tested in trials with a discontinuation design, 1 in which patients who have already responded to a treatment are randomly assigned to either ongoing treatment or placebo. Such studies provide a measure of the benefit of maintenance treatment over discontinuation. However, discontinuation studies have several limitations. The first is common to psychiatric treatment studies generally; how and when should we assess whether a patient's symptoms have changed after discontinuation? The second is more specific to discontinuation designs; the selection of patients based on a positive response to that treatment is likely to inflate the apparent beneficial effect of the treatment, because that subgroup of patients has the most to lose from stopping treatment.en
dc.description.urihttps://doi.org/10.1016/S2215-0366(17)30054-8en
dc.language.isoenen
dc.subjectDepressive Disordersen
dc.subjectAntidepressant Drugsen
dc.titleSymptom trajectories in discontinuation trials.en
dc.typeArticleen
Appears in Collections:Depressive Disorders

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.